180 related articles for article (PubMed ID: 35508892)
1. Survival analyses from the CENTAUR trial in amyotrophic lateral sclerosis: Evaluating the impact of treatment crossover on outcomes.
Paganoni S; Watkins C; Cawson M; Hendrix S; Dickson SP; Knowlton N; Timmons J; Manuel M; Cudkowicz M
Muscle Nerve; 2022 Aug; 66(2):136-141. PubMed ID: 35508892
[TBL] [Abstract][Full Text] [Related]
2. Analysis of sodium phenylbutyrate and taurursodiol survival effect in ALS using external controls.
Paganoni S; Quintana M; Sherman AV; Vestrucci M; Wu Y; Timmons J; Cudkowicz M;
Ann Clin Transl Neurol; 2023 Dec; 10(12):2297-2304. PubMed ID: 37807839
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis.
Paganoni S; Hendrix S; Dickson SP; Knowlton N; Macklin EA; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson TD; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Hall M; Kittle G; Eydinov M; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; St Pierre ME; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Yu ZF; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
Muscle Nerve; 2021 Jan; 63(1):31-39. PubMed ID: 33063909
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial.
Paganoni S; Hendrix S; Dickson SP; Knowlton N; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson TD; Jackson C; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha SS; Miller TM; Scelsa SN; Vu TH; Fournier C; Johnson KM; Swenson A; Goyal N; Pattee GL; Babu S; Chase M; Dagostino D; Hall M; Kittle G; Eydinov M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Yu H; Cohen J; Klee J; Tanzi R; Gilbert W; Yeramian P; Cudkowicz M
J Neurol Neurosurg Psychiatry; 2022 May; 93(8):871-5. PubMed ID: 35577511
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
Sun Y; Li X; Bedlack R
Expert Rev Neurother; 2023 Jan; 23(1):1-7. PubMed ID: 36705941
[TBL] [Abstract][Full Text] [Related]
6. Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial.
Bowser R; An J; Mehta L; Chen J; Timmons J; Cudkowicz M; Paganoni S
J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):605-608. PubMed ID: 38050066
[TBL] [Abstract][Full Text] [Related]
7. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson T; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Dickson SP; Ellison N; Hall M; Hendrix K; Kittle G; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
N Engl J Med; 2020 Sep; 383(10):919-930. PubMed ID: 32877582
[TBL] [Abstract][Full Text] [Related]
8. Sodium phenylbutyrate-taurursodiol access, adherence and adverse event in patients with amyotrophic lateral sclerosis: Experience at one center in the United States.
Mamarabadi M; Fafoutis E; Geronimo A; Walsh S; Simmons Z
Muscle Nerve; 2024 Aug; 70(2):204-209. PubMed ID: 38828849
[TBL] [Abstract][Full Text] [Related]
9. A single ALS center experience with clinical use of sodium phenylbutyrate-taurursodiol.
Quinn C; Baer M; Amado DA; Kelley M; Elman L
Muscle Nerve; 2024 Jul; 70(1):148-151. PubMed ID: 38670927
[TBL] [Abstract][Full Text] [Related]
10. Sodium Phenylbutyrate and Taurursodiol: A New Therapeutic Option for the Treatment of Amyotrophic Lateral Sclerosis.
Alqallaf A; Cates DW; Render KP; Patel KA
Ann Pharmacother; 2024 Feb; 58(2):165-173. PubMed ID: 37269231
[TBL] [Abstract][Full Text] [Related]
11. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
13. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908
[TBL] [Abstract][Full Text] [Related]
14. Managed care considerations to improve health care utilization for patients with ALS.
Wong W
Am J Manag Care; 2023 Jun; 29(7 Suppl):S120-S126. PubMed ID: 37433093
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial.
Cudkowicz M; Genge A; Maragakis N; Petri S; van den Berg L; Aho VV; Sarapohja T; Kuoppamäki M; Garratt C; Al-Chalabi A;
Lancet Neurol; 2021 Oct; 20(10):821-831. PubMed ID: 34536404
[TBL] [Abstract][Full Text] [Related]
16. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis.
Brooks BR; Pioro EP; Sakata T; Takahashi F; Hagan M; Apple S
Muscle Nerve; 2023 Oct; 68(4):397-403. PubMed ID: 37525592
[TBL] [Abstract][Full Text] [Related]
17. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME; van den Berg LH; Shefner JM; Mitsumoto H; Mora JS; Ludolph A; Hardiman O; Bozik ME; Ingersoll EW; Archibald D; Meyers AL; Dong Y; Farwell WR; Kerr DA;
Lancet Neurol; 2013 Nov; 12(11):1059-67. PubMed ID: 24067398
[TBL] [Abstract][Full Text] [Related]
18. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.
; Morrison KE; Dhariwal S; Hornabrook R; Savage L; Burn DJ; Khoo TK; Kelly J; Murphy CL; Al-Chalabi A; Dougherty A; Leigh PN; Wijesekera L; Thornhill M; Ellis CM; O'Hanlon K; Panicker J; Pate L; Ray P; Wyatt L; Young CA; Copeland L; Ealing J; Hamdalla H; Leroi I; Murphy C; O'Keeffe F; Oughton E; Partington L; Paterson P; Rog D; Sathish A; Sexton D; Smith J; Vanek H; Dodds S; Williams TL; Steen IN; Clarke J; Eziefula C; Howard R; Orrell R; Sidle K; Sylvester R; Barrett W; Merritt C; Talbot K; Turner MR; Whatley C; Williams C; Williams J; Cosby C; Hanemann CO; Iman I; Philips C; Timings L; Crawford SE; Hewamadduma C; Hibberd R; Hollinger H; McDermott C; Mils G; Rafiq M; Shaw PJ; Taylor A; Waines E; Walsh T; Addison-Jones R; Birt J; Hare M; Majid T
Lancet Neurol; 2013 Apr; 12(4):339-45. PubMed ID: 23453347
[TBL] [Abstract][Full Text] [Related]
19. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Cochrane Database Syst Rev; 2002; (2):CD001447. PubMed ID: 12076411
[TBL] [Abstract][Full Text] [Related]
20. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
